Limitations included the relatively small study cohort treated at a single center. A multicenter trial with a larger sample size is warranted, they added.
The study was funded by the Jiangsu Province Department of Health. Dr. Pan reported ties to Gilead, Bristol Myers Squibb, Novartis, Idenix, Roche, Schering Plough, Onyx, Three Rivers, Salix, Genentech, Vertex, and Pharmasset.